Bone conduction treatment determination and care pathway
What you'll find on this page
- How to the determine appropriate Cochlear™ Bone Conduction Solutions for patients
- Patient fitting and outcome evaluation recommendations
- In-depth resources, including a comprehensive protocol for candidacy, evaluation, and fitting bone conduction solutions
Treatment determination and care pathway
Follow these steps for a consistent and streamlined candidacy and treatment process. For more details, please go to the Resources section to download the Bone Conduction Protocol.
Cochlear Bone Conduction Solutions candidacy, evaluation and fitting protocol
Candidacy identification
Assess audiological status, medical etiologies and impact to daily life to determine if bone conduction may be an appropriate solution. Consider the following:
- Type of hearing loss (conductive or mixed hearing loss, single-sided deafness)
- Common etiologies (microtia/atresia, chronic otitis media, middle ear dysfunction/ossicular disease, or conditions contraindicating reliable use of conventional hearing aids)
- Daily interactions (struggle with communication, need for reliable and consistent hearing, and quality of life)
Demonstration and evaluation
Allow patients to experience hearing through bone conduction with a demonstration.
Conduct a bone conduction evaluation to assess the candidate’s performance to assist with treatment determination, help predict outcomes, and collect a baseline for continued monitoring.
Treatment determination
Develop an audiological treatment plan in conjunction with medical treatment, to meet patient lifestyle needs.
Patient qualification
|
RecommendationCochlear™ Osia® System
|
Patient qualification
|
RecommendationCochlear Osia System
or Conduct a cochlear implant evaluation for a Cochlear Nucleus® System: |
Patient qualification
|
RecommendationCochlear™ Baha® Start with Baha 6 Max Sound Processor worn with a SoundArc™ or Softband |
Additional recommendations for specific cases
Patient with factors that preclude an Osia System |
RecommendationCochlear™ Baha® Connect with Baha 6 Max Sound Processor |
Patient with bone conduction PTA threshold between 55-65 dB |
RecommendationCochlear Baha Connect with Baha 5 SuperPower Sound Processor or Conduct a cochlear implant evaluation for a Cochlear Nucleus® System: |
Patient suitable for a Baha Solution and requires additional clearance between the skin and the Baha 6 Max Sound Processor |
RecommendationConsider the Baha 6 Max Sound Processor with the 2mm Extended snap coupling, instead of the LowPro™ snap coupling |
Patient treatment, fitting and monitoring
Provide and evaluate improved sound quality and speech intelligibility with comfortable wear for the recipient to use their bone conduction solution to the maximum potential.
Consider utilizing available Remote Care solutions to provide quality care without the need for patients to visit the clinic.
Resources
- Candidacy, evaluation and fitting quick guide
- Candidacy, evaluation and fitting protocol for Cochlear Bone Conduction devices
- Bone Conduction portfolio referral criteria
- Cochlear Solutions: Impact and considerations for SSD
- Bone Conduction portfolio poster - How Bone Conduction works (for candidates)
Disclaimer
This material is intended for health professionals. If you are a consumer, please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always read the instructions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information.
For a full list of Cochlear’s trademarks, please visit our Terms of Use page.
*In the United States and Canada, the placement of a bone-anchored implant is contraindicated in children below the age of 5. In the United States, the Osia 2 System is cleared for children ages twelve and older. In Canada, the Osia 2 System is approved for children ages five and older.
†In the United States and Canada, the Nucleus System for single-sided deafness is cleared for children ages five and older